Vlado Perkovic's Publications

Waijer SW, Gansevoort RT, Bakris GL et alii
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
Journal articles
2021
Clin J Am Soc Nephrol
Wong MG, Lv J, Hladunewich MA et alii
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics
Journal articles
2021
American Journal of Nephrology
Feng KY, Li JW, Ianus J et alii
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
Journal articles
2021
Diabetes
Heerspink HJL, Xie D, Bakris G et alii
Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial
Journal articles
2021
Journal of the American Society of Nephrology
Young TK, Li JW, Kang A et alii
Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program
Journal articles
2021
Diabetologia
Neuen BL, Oshima M, Perkovic V et alii
Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial
Journal articles
2021
European Heart Journal
Sen T, Li J, Neuen BL et alii
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Journal articles
2021
Diabetologia
Rahimi K, Bidel Z, Nazarzadeh M et alii
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis
Journal articles
2021
The Lancet
Wheeler DC, Weir MR, Gogate J et alii
Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial
Conference Abstracts
2021
in DIABETOLOGIA
Kang A, Arnold R, Gallagher M et alii
Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial
Journal articles
2021
Clinical Journal of the American Society of Nephrology
Mann JFE, Buse JB, Idorn T et alii
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis
Journal articles
2021
Diabetes
Kalantar-Zadeh K, Jafar TH, Nitsch D et alii
Chronic kidney disease
Journal articles
2021
The Lancet
Heerspink HJL, Stack AG, Terkeltaub R et alii
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia
Journal articles
2021
NEPHROLOGY DIALYSIS TRANSPLANTATION
Yeung E, Bello AK, Levin A et alii
Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey
Journal articles
2021
BMJ Open
Wang KM, Li JW, Bhalla V et alii
Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program
Journal articles
2021
Endocrinology
Arnott C, Li JW, Cannon CP et alii
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Conference Abstracts
2021
in Diabetes
Perkovic V, Rovin B, Zhang H et alii
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS
Conference Abstracts
2021
in NEPHROLOGY DIALYSIS TRANSPLANTATION
Yi TW, Smyth B, Kang A et alii
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial
Journal articles
2021
DIABETES
Liao J, Kang A, Xia C et alii
The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial
Journal articles
2021
DIABETES
Jun M, Harris K, Heerspink HJL et alii
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial
Journal articles
2021
Diabetes
Koomen JV, Stevens J, Bakris G et alii
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Journal articles
2021
Clinical Pharmacology and Therapeutics
Perkovic V, Blackorby A, Cizman B et alii
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS
Journal articles
2021
Nephrology Dialysis Transplantation
Perkovic V, Rovin B, Zhang H et alii
MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS
Journal articles
2021
Nephrology Dialysis Transplantation
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (vol 8, pg 1482, 2021)
Journal articles
2021
ESC HEART FAILURE
Wheeler DC, Weir M, Gogate J et alii
EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL
Journal articles
2021
NEPHROLOGY DIALYSIS TRANSPLANTATION
Weir MR, Slee A, Sun T et alii
Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program
Journal articles
2021
CLINICAL KIDNEY JOURNAL

Previous Next

Vlado Perkovic's Publications

The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.

The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics

Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist: A prespecified analysis from the SONAR trial

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

Effects of canagliflozin on major adverse cardiovascular events by baseline albuminuria: integrated analyses from the CANVAS Program and CREDENCE trial

Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Chronic kidney disease

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Current status of health systems financing and oversight for end-stage kidney disease care: A cross-sectional global survey

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (vol 8, pg 1482, 2021)

EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country